Hot Features
Premium
Trade like a pro: Leverage real-time discussions and market-moving ideas to outperform.
Period:
Draw Mode:
| Volume | 51 |
|
|||||
| News | - | ||||||
| Day High | Low High |
||||||
| Day Low | |||||||
| Share Name | Share Symbol | Market | Stock Type |
|---|---|---|---|
| Adhera Therapeutics Inc (PK) | ATRX | OTCMarkets | Common Stock |
| Price Change | Price Change % | Share Price | Last Trade
|
|
|---|---|---|---|---|
| 0.00 | 0.00% | 0.0039 | 15:15:13 |
| Open Price | Low Price | High Price | Close Price | Previous Close |
|---|---|---|---|---|
| 0.0039 | 0.0039 |
| Trades | Shares Traded | Average Volume | 52 Week Range |
|---|---|---|---|
| 2 | 51 | - | 0.003 - 0.1499 |
| Last Trade | Type | Quantity | Price | Currency |
|---|---|---|---|---|
| 14:20:54 | 50 | US$ 0.0145 | USD |
Adhera Therapeutics Inc (PK) Financials
| Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
|---|---|---|---|---|---|---|
| 7.15M | 3.84M | 3.00M | 0 | -2.73M | -0.38 | - |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | - | - | - |
Adhera Therapeutics (PK) News
| Date | Time | Source | News Article |
|---|---|---|---|
| 1/30/2024 | 15:00 | Edgar (US Regulatory) | Form SEC STAFF ACTION - SEC Staff Action: ORDER |
| 1/18/2024 | 15:25 | Edgar (US Regulatory) | Form 8-K - Current report |
| 1/16/2024 | 15:01 | Edgar (US Regulatory) | Form 8-K - Current report |
| 11/29/2023 | 15:01 | Edgar (US Regulatory) | Form 8-K - Current report |
| 11/20/2023 | 15:51 | Edgar (US Regulatory) | Form 10-Q - Quarterly report [Sections 13 or 15(d)] |
| 11/15/2023 | 15:35 | Edgar (US Regulatory) | Form NT 10-Q - Notification of inability to timely file Form.. |
| 10/12/2023 | 15:58 | Edgar (US Regulatory) | Form 8-K - Current report |
| 8/21/2023 | 14:32 | Edgar (US Regulatory) | Form 10-Q - Quarterly report [Sections 13 or 15(d)] |
| 8/15/2023 | 15:05 | Edgar (US Regulatory) | Form NT 10-Q - Notification of inability to timely file Form.. |
| 6/29/2023 | 15:54 | Edgar (US Regulatory) | Form 8-K - Current report |
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical ATRX Price Data
| Period † | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 0.0045 | 0.0045 | 0.003 | 0.0039326 | 200,071 | -0.0006 | -13.33% |
| 1 Month | 0.006 | 0.009 | 0.003 | 0.0043335 | 75,342 | -0.0021 | -35.00% |
| 3 Months | 0.0145 | 0.0175 | 0.003 | 0.0099798 | 86,605 | -0.0106 | -73.10% |
| 6 Months | 0.014 | 0.0475 | 0.003 | 0.0151505 | 169,432 | -0.0101 | -72.14% |
| 1 Year | 0.1499 | 0.1499 | 0.003 | 0.0164972 | 140,805 | -0.146 | -97.40% |
| 3 Years | 0.065 | 1.09 | 0.003 | 0.12007 | 129,482 | -0.0611 | -94.00% |
| 5 Years | 0.20 | 1.09 | 0.003 | 0.1140727 | 84,637 | -0.1961 | -98.05% |
Adhera Therapeutics (PK) Description
| Adhera Therapeutics is a clinical stage biopharmaceutical company focused on identifying advanced drug candidates that may qualify for accelerated developmental pathways. The Company has recently licensed two drug candidates, MLR-1019 and MLR-1023, from the Melior Discovery family of companies. Adhera is developing MLR-1023 (tolimidone) as a new drug for Type I diabetes with a focus on C-peptide positive patients. MLR-1023, a lyn kinase activator, has demonstrated exceptional clinical safety and tolerability in over 700 patients in Phase 2a and Phase 2b Type 2 diabetes studies. MLR-1019 (armesocarb) is a new class of drug for Parkinson's Disease (PD) and represents the only drug to address both movement and non-movement symptoms of PD. Armesocarb is the active enantiomer in mesocarb, a drug marketed in Europe for 37 years for various psychiatric and central nervous system indications. In addition to advancing both drug candidates in Phase 2 clinical trials, the Company remains active in exploring other advanced drug development opportunities while maintaining its legacy assets, including CEQ508, an oral delivery of small interfering RNA (siRNA) against beta-catenin, to suppress polyps in the precancerous syndrome and orphan indication Familial Adenomatous Polyposis (FAP). |
